Home > Search Clinical Trials > Cancer - Urologic, Prostate
Clinical Trials: Cancer - Urologic, Prostate
IRB No. 14-184-3.2 (Dr. Jessica Clement, PI): A Phase II, Multicenter, Single-Arm Study of Atezolizumab in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
The purpose of this study is to look at the effects, good or bad, of MPDL3280A on you and your bladder cancer. MPDL3280A is an experimental drug, which means that health authorities have not approved MPDL3280A for the treatment of bladder cancer. MPDL3280A is an antibody (a protein produced by the body's immune system) that affects the immune system by blocking the programmed death-ligand 1 (PD-L1) pathway. The PD-L1 pathway is involved in regulating the body's natural immune response, but tumors can take advantage of this regulation to partially resist or evade the immune system. By blocking the PD L1 pathway, MPDL3280A may help your immune system stop or reverse the growth of tumors. Blood, tissue samples, and related medical information collected during this study will be used by Sponsor researchers and other researchers partnering with the Sponsor for research related to bladder cancer and how MPDL3280A works.